CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas
J. M. Pita, E. Raspe, K. Coulonval, M. Decaussin-Petrucci, M. Tarabichi, G. Dom, F. Libert, L. Craciun, G. Andry, L. Wicquart, E. Leteurtre, C. Tresallet, L. A. Marlow, J. A. Copland, C. Durante, , P. P. Roger
This study shows that CDK4 phosphorylation status predicts response to CDK4/6 inhibitors in thyroid carcinomas and supports combining them with BRAF/MEK inhibitors to prevent resistance.
bioRxiv · Jun 5, 2023Cancer Biology